» Articles » PMID: 25132866

Treatment of Crohn's Disease Complicated with Myelodysplastic Syndrome Via Allogeneic Hematopoietic Stem Cell Transplantation: Case Report and Literature Review

Overview
Specialty Gastroenterology
Date 2014 Aug 19
PMID 25132866
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract arising in individuals with genetic predisposing factors and abnormalities of the immune system. Myelodysplastic syndrome (MDS), an acquired clonal hematologic disorder, is characterized by peripheral blood cytopenia, dysplastic changes in several types of hematopoietic cells of the bone marrow and peripheral blood, and a high risk of transformation to acute leukemia. CD rarely occurs in combination with MDS, and MDS treatment with hematopoietic stem cell transplantation (HSCT) has not been frequently reported. We report the case of a 50-year-old Chinese male who presented with abdominal pain, diarrhea, and fatigue. CD was diagnosed by colonoscopy, imaging studies, and pathological examination. He was initially treated with mesalazine and prednisone and thereafter he presented with pancytopenia. MDS (RAEB-I) was diagnosed by bone marrow examination, and karyotyping revealed 47, XY, +8. The patient was treated with thalidomide, andriol, and decitabine. Allogeneic HSCT was performed with a human leukocyte antigen-matched sibling as the donor. The patient is currently well at 14 months after HSCT, without abdominal pain, diarrhea, or fatigue. HSCT may be a promising treatment option for patients with combined CD and MDS.

Citing Articles

Autoimmune diseases and myelodysplastic syndromes.

Cheffai A, Kechida M Reumatologia. 2024; 62(1):52-57.

PMID: 38558894 PMC: 10979376. DOI: 10.5114/reum/184157.


Allogeneic hematopoietic stem cell transplantation for Crohn disease complicated with myelodysplastic syndrome: A case report.

Zhang Y, Lou L, Shi X, Lu S, Zhang L, Huang X Medicine (Baltimore). 2020; 99(10):e19450.

PMID: 32150101 PMC: 7478571. DOI: 10.1097/MD.0000000000019450.


Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.

Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H Intern Med. 2019; 58(14):2029-2033.

PMID: 30996178 PMC: 6702013. DOI: 10.2169/internalmedicine.2495-18.

References
1.
Leung Y, Geddes M, Storek J, Panaccione R, Beck P . Hematopoietic cell transplantation for Crohn's disease; is it time?. World J Gastroenterol. 2006; 12(41):6665-73. PMC: 4125673. DOI: 10.3748/wjg.v12.i41.6665. View

2.
Burt R, Craig R, Milanetti F, Quigley K, Gozdziak P, Bucha J . Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010; 116(26):6123-32. DOI: 10.1182/blood-2010-06-292391. View

3.
Epling-Burnette P, McDaniel J, Wei S, List A . Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opin Emerg Drugs. 2012; 17(4):519-41. DOI: 10.1517/14728214.2012.736487. View

4.
Sullivan K, Muraro P, Tyndall A . Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2009; 16(1 Suppl):S48-56. PMC: 3448948. DOI: 10.1016/j.bbmt.2009.10.034. View

5.
Piccin A, Cortelazzo S, Rovigatti U, Bourke B, Smith O . Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia. Am J Hematol. 2010; 85(8):634. DOI: 10.1002/ajh.21755. View